| |
Total
|
Completers
|
Non-completers
|
p value
|
|---|
|
N = 100
|
N = 51
|
N = 49
|
|---|
|
n
|
%
|
%
|
%
|
|---|
|
Exit status
| | | | |
< 0.0013
|
|
Voluntary
|
85
|
85
|
51
|
34
| |
|
Program complete
|
23
|
23
|
23
|
0
| |
|
Program incomplete
|
15
|
15
|
0
|
15
| |
|
Progression to therapeutic community
|
28
|
28
|
28
|
0
| |
|
Reduction complete
|
19
|
19
|
0
|
19
| |
|
Involuntary
|
15
|
15
|
0
|
15
| |
|
Reduction complete
|
9
|
9
|
0
|
9
| |
|
Reduction incomplete
|
6
|
6
|
0
|
6
| |
|
Length of stay (LOS) in daysa
|
< 0.001b
|
|
< 47
|
25
|
25
|
0
|
25
| |
|
47–82
|
23
|
23
|
3
|
20
| |
|
> 82
|
52
|
52
|
48
|
4
| |
|
Gender
| | | | | |
|
Male
|
56
|
56
|
53.1
|
58.8
|
0.562b
|
|
Female
|
44
|
44
|
46.9
|
41.2
| |
|
Age (years)
| | | | | |
|
< 30
|
9
|
9
|
5.9
|
12.2
| |
|
30–39
|
43
|
43
|
39.2
|
46.9
| |
|
40–49
|
37
|
37
|
56.8
|
32.7
| |
|
> 50
|
11
|
11
|
13.7
|
8.2
| |
|
Mean age in years (sd)
|
38.9
|
(7.7)
|
40.1 (7.7)
|
37.6 (7.5)
|
0.094c
|
|
Rurality (n = 98)
| | | | |
0.901c
|
|
MMM1
|
63
|
62
|
64.7
|
63.8
| |
|
MMM2
|
3
|
3
|
2.0
|
4.3
| |
|
MMM3
|
9
|
8
|
7.8
|
10.6
| |
|
MMM4
|
15
|
15
|
17.6
|
12.8
| |
|
MMM5
|
8
|
8
|
7.8
|
8.5
| |
|
Mean MMM score (sd)
|
2.0
|
(1.5)
|
2.0 (1.5)
|
2.0 (1.4)
|
0.890c
|
|
Primary substance
|
0.781b
|
|
Analgesics
|
80
|
80
|
82.4
|
77.6
| |
|
Sedatives and hypnotics
|
12
|
12
|
9.8
|
14.3
| |
|
Stimulants and antipsychotics
|
8
|
8
|
7.8
|
8.2
| |
|
Method of use
| | | | |
0.773b
|
|
Inject
|
65
|
65
|
70.6
|
59.2
| |
|
Ingest
|
25
|
25
|
19.6
|
30.6
| |
|
Absorption
|
2
|
2
|
2.0
|
2.0
| |
|
Smoke
|
4
|
4
|
3.9
|
4.1
| |
|
Sniff (powder)
|
1
|
1
|
2.0
|
0.0
| |
|
Other
|
3
|
3
|
2.0
|
2.0
| |
|
Last injected (n = 99)
|
0.614b
|
|
Within previous 3 months
|
65
|
65
|
66.7
|
63.3
| |
|
More than 3, less than 12 months
|
12
|
12
|
13.7
|
10.2
| |
|
More than 12 months ago
|
11
|
11
|
11.8
|
10.2
| |
|
Never Injected
|
12
|
12
|
7.8
|
16.3
| |
- sd standard deviation, MMM Modified Monash Model
- aA completer stay of less than 91 days indicates an early attainment of abstinence and progression to the therapeutic communities program at the same facility
- bp value for Chi-squared test
- cp value for t-test
